3-Hydroxy-5-tert.butyl-1,2,4-oxadiazol | 39200-06-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 3-Hydroxy-5-tert.butyl-1,2,4-oxadiazol
• 英文别名: 5-Tert-butyl-1,2,4-oxadiazol-3-one
• CAS: 39200-06-1
• 化学式: C₆H₁₀N₂O₂
• 分子量: 142.158
• InChiKey: SEIGTPRKKORVMS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  50.7
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• [EN] CANNABINOID RECEPTOR MODULATORS<br/>[FR] MODULATEURS DU RÉCEPTEUR DE CANNABINOÏDES
  申请人：7TM PHARMA AS

  公开号：WO2009074782A1

  公开（公告）日：2009-06-18

  Compounds of formula (I) are modulators of cannabinoid receptor CB1, useful inter alia for treatment of obesity: Formula (I). Wherein:X is a bond, or a divalent radical selected from -C(R10)(R11)-*, -C(R10)(R11)-O-*, -C(R10)(R11)CH2-*, -C(R10)(R11)CH2-O-*, -CH2C(R10)(R11)-*, -CH2C(R10)(R11) -O-*. and -CH2-O-C(R10)(R11)-*, wherein the bond indicated by an asterisk is attached to the pyrazole ring; Z is a carboxyl isostere radical selected from the group specified; R3 is hydrogen, (C1-C)aIkyI or (C1C3)fluoroalkyl; R4 is a radical of formula -(AIk1)P-(Q1)r (L)s -Q2 wherein p, r, s, AIk1, L, Q1 and Q2 are as specified; or R3 and R4 taken together with the nitrogen to which they are attached form a cyclic amino ring of 4 to 7 ring atoms which is optionally substituted by a radical of formula -(L)s-Q2 wherein s, L and Q2 are as defined above, or by an optional substituent selected from hydroxy, methoxy, -NH2-, or mono- or di-(C1C3)alkylamino; R5, R6, R7 and R8 are each independently selected from hydrogen -F, -Cl, -Br, -CN, (C1-C3)alkyl, (C1C3)fluoroalkyl, cyclopropyl, and -OR9; R10 is hydrogen, (C1C3)alkyl, hydroxyl or NH2, and R11 is hydrogen or (C1-C3)alkyl; or R10 and R11 taken together with the carbon atom to which they are attached form a (C3-C5)cycloalkyl ring.

  式(I)的化合物是大麻素受体CB1的调节剂，可用于治疗肥胖：式(I)。其中：X是一个键，或者从-C(R10)(R11)-*、-C(R10)(R11)-O-*、-C(R10)(R11)CH2-*、-C(R10)(R11) -O-*、- C(R10)(R11)-*、- C(R10)(R11) -O-*中选择的二价基团。和- -O-C(R10)(R11)-*，其中星号表示连接到吡唑环的键；Z是从指定组中选择的羧基异构基团；R3是氢、(C1-C)aIkyI或(C1C3)氟烷基；R4是式-(AIk1)P-(Q1)r(L)s-Q2的基团，其中p、r、s、AIk1、L、Q1和Q2如指定；或者R3和R4与它们连接的氮一起形成一个含有4至7个环原子的环氨基环，该环可选地被式-(L)s-Q2中的基团或上述定义的s、L和Q2定义的基团取代，或者通过一个可选的取代基团选择自羟基、甲氧基、-NH2-或单或双-(C1C3)烷基胺；R5、R6、R7和R8分别独立地选择自氢、-F、-Cl、-Br、-CN、(C1-C3)烷基、(C1C3)氟烷基、环丙基和-OR9；R10是氢、(C1C3)烷基、羟基或NH2，R11是氢或(C1-C3)烷基；或者R10和R11与它们连接的碳原子一起形成一个(C3-C5)环烷基环。
• Novel Substituted Bicyclic Aromatic Compounds as S-Nitrosoglutathione Reductase Inhibitors
  申请人：N30 Pharmaeuticals, Inc.

  公开号：US20140329821A1

  公开（公告）日：2014-11-06

  The present invention is directed to novel substituted bicyclic aromatic compounds useful as S-nitrosoglutathione reductase (GSNOR) inhibitors, pharmaceutical compositions comprising such compounds, and methods of making and using the same.

  本发明涉及一种新型的取代双环芳香化合物，其作为S-亚硝基谷胱甘肽还原酶（GSNOR）抑制剂具有用途，包括含有这种化合物的制药组合物以及制备和使用这种化合物的方法。
• COMPOUNDS THAT ARE S1P MODULATING AGENTS AND/OR ATX MODULATING AGENTS
  申请人：BIOGEN IDEC MA INC.

  公开号：US20150183741A1

  公开（公告）日：2015-07-02

  Compounds of formula (I) can modulate the activity of one or more SIP receptors and/or the activity of autotaxin (ATX).

  公式(I)的化合物可以调节一个或多个SIP受体的活性和/或自动趋化素(ATX)的活性。
• ATX MODULATING AGENTS
  申请人：BIOGEN IDEC MA INC.

  公开号：US20150210647A1

  公开（公告）日：2015-07-30

  Disclosed are bicyclic aryl compounds of formula (I), that can modulate the activity of the autotaxin (ATX) enzyme. This invention further relates to compounds that are ATX inhibitors, and methods of making and using such compounds in the treatment of demyelination due to injury or disease, as well as for treating proliferative disorders such as cancer.

  本发明公开了式（I）的双环芳基化合物，可以调节自体移行素（ATX）酶的活性。本发明还涉及ATX抑制剂化合物以及制备和使用这种化合物治疗因损伤或疾病引起的脱髓鞘和治疗增生性疾病如癌症的方法。
• S1P AND/OR ATX MODULATING AGENTS
  申请人：BIOGEN IDEC MA INC.

  公开号：US20150274663A1

  公开（公告）日：2015-10-01

  Compounds of formula (I) wherein: X is —O—, —S(O) r —, —CH 2 —, or —NR—, wherein r is 0, 1, or 2; X 1 , X 2 , and X 5 are each independently CR 7 or N; one of X 3 or X 4 is C and is attached by a single bond to -L-, and the other is CR 7 or N, provided that no more than three of X 1 , X 2 , X 3 , X or X 5 are N; Ring A is monocyclic C 5-6 scycloalkyl or a 5- to 6-membered monocyclic heterocyclyl comprising from 1 to 5 heteroatoms independently selected from N, S, or O; wherein Ring A is further optionally substituted with from 1 to 3 R 4 ; provided that Ring A is not morpholinyl, thiomorpholinyl or tetrahydro-2H-pyranyl; L is a bond, —O—, —NR—, —S(O) n —, —CH 2 —, or —C(O)—, wherein n is 0, 1, or 2; 1 2 L 1 is an C 1-8 alkylene, C 3-s cycloalkylene, —CH 2 -L 2 -, or a 3- to 8-membered heterocyclylene comprising 1 to 5; R 1 is C 6-20 alkyl or a monocyclic C 3-8 cycloalkyl; wherein said C 3-8 cycloalkyl is substituted with at least one R 6 and may be optionally substituted with from 1 to 5 additional R 6 substituents, wherein R 6 for each occurrence is independently selected; and R 2 is —C(O)OR 3 , —C(O)N(R 3 )—S(O) 2 R 3 , —S(O) 2 OR 3 , —C(O)NHC(O)R 3 , —Si(O)OH, —B(OH) 2 , —N(R 3 )S(O) 2 R 3 , —S(O) 2 N(R 3 ) 2 , —O—P(O)(OR 3 ) 2 , or —P(O)(OR 3 ) 2 , —CN, —S(O) 2 NHC(O)R 3 , —C(O)NHS(O) 2 R3, —C(O)NHOH, —C(O)NHCN, —CH(CF 3 )OH, —C(CF 3 ) 2 OH, or a selected heteroaryl or heterocyclyl; and pharmaceutically acceptable salts thereof, can modulate the activity of one or more SIP receptors and/or the activity of autotaxin (ATX).

  化合物的公式（I），其中：X为—O—，—S（O）r—，—CH2—或—NR—，其中r为0、1或2；X1、X2和X5各自独立地为CR7或N；X3或X4中的一个为C，并通过单键连接到-L-，另一个为CR7或N，前提是X1、X2、X3、X或X5中不超过三个为N；环A为单环C5-6环烷基或由1至5个杂原子独立选择的N、S或O构成的5-至6元单环杂环基；其中环A还可以用1至3个R4取代；前提是环A不是吗啡啶基、硫代吗啡啶基或四氢-2H-吡喃基；L为键，—O—，—NR—，—S（O）n—，— —或—C（O）—，其中n为0、1或2；L1为C1-8烷基、C3-环烷基、— -L2-或1至5个杂环基，其中每个杂环基包含1至5个原子；R1为C6-20烷基或单环C3-8环烷基；其中所述的C3-8环烷基被至少一个R6取代，并且可以选择地用1至5个额外的R6取代，其中每个出现的R6是独立选择的；R2为—C（O）OR3、—C（O）N（R3）—S（O）2R3、—S（O）2OR3、—C（O）NHC（O）R3、—Si（O）OH、—B（OH）2、—N（R3）S（O）2R3、—S（O）2N（R3）2、—O—P（O）（OR3）2或—P（O）（OR3）2、—CN、—S（O）2NHC（O）R3、—C（O）NHS（O）2R3、—C（O）NHOH、—C（O）NHCN、—CH（CF3）OH、—C（ ）2OH或所选的杂芳基或杂环基；以及其药学上可接受的盐，可以调节一个或多个SIP受体和/或自体移动素（ATX）的活性。